Paid articlePaywallmRNA cancer vaccine: Setback for Mainz-based BioNTech after soaring success:
After strong test data from its US competitor Moderna, BioNTech's stock price ...
mittelhessen.de/wirtschaft/wirtschaft-hessen-und-rheinland-pfalz/mrna-krebsimpfstoff-nach-hoehenflug-rueckschlag-fuer-biontech-6171151
Story Details
| Last Updated | |
| Total Articles | 6 |
Main Topics
vaccine that either treats existing cancer or prevents development of cancer
News on this topic
Paid articlePaywall mRNA cancer vaccine: After soaring high, setback for Mainz-based BioNTech: After strong test data from its US competitor Moderna, BioNTech's stock price shot ...
allgemeine-zeitung.de/wirtschaft/wirtschaft-hessen-und-rheinland-pfalz/mrna-krebsimpfstoff-nach-hoehenflug-rueckschlag-fuer-biontech-6171151
Paid articlePaywall mRNA cancer vaccine: After a meteoric rise, a setback for Mainz-based BioNTech: After strong test data from US competitor Moderna, BioNTech's stock price ...
echo-online.de/wirtschaft/wirtschaft-hessen-und-rheinland-pfalz/mrna-krebsimpfstoff-nach-hoehenflug-rueckschlag-fuer-biontech-6171151
Paid articlePaywall mRNA cancer vaccine: Setback for Mainz-based BioNTech after soaring high: After strong test data from its US competitor Moderna, BioNTech's stock price shot ...
main-spitze.de/wirtschaft/wirtschaft-hessen-und-rheinland-pfalz/mrna-krebsimpfstoff-nach-hoehenflug-rueckschlag-fuer-biontech-6171151
More articles on this subject
Previous
Paid articlePaywall mRNA cancer vaccine: After soaring high, setback for Mainz-based BioNTech: After strong test data from its US competitor Moderna, BioNTech's stock price shot ...
wiesbadener-kurier.de/wirtschaft/wirtschaft-hessen-und-rheinland-pfalz/mrna-krebsimpfstoff-nach-hoehenflug-rueckschlag-fuer-biontech-6171151
mRNA cancer vaccine: Setback for Mainz-based BioNTech after meteoric rise: After strong test data from its US competitor Moderna, BioNTech's stock price shot ...
gnz.de/wirtschaft/wirtschaft-hessen-und-rheinland-pfalz/mrna-krebsimpfstoff-nach-hoehenflug-rueckschlag-fuer-biontech-6180353
Next
Similar to This
Previous
Paid articlePaywall Moderna Earnings Preview: The Melanoma Breakthrough Is Real, But $221 Is Way Too Much
seekingalpha.com/article/4962734-moderna-earnings-preview-the-melanoma-breakthrough-is-real-but-221-is-way-too-much
STAT Oct 30
Paid articlePaywall Assessing Merck and Moderna’s mRNA cancer vaccine: STAT reporters discuss the latest data from Merck, Moderna, Amgen, and Roche presented at the biggest European ...
statnews.com/2026/10/30/readout-loud-podcast-oncology-cancer-vaccine-moderna-merck-amgen-roche/
Bernd Förtsch on BioNTech: Resignation is overdue: Shareholder Bernd Förtsch sharply criticizes the events at the Corona superstar.
deraktionaer.de/artikel/aktien/bernd-foertsch-ueber-biontech-ruecktritt-ist-ueberfaellig-20409989.html
Moderna stock knows no bounds - | what's going on with BioNTech?: The stock has roughly tripled since the positive data was released.
deraktionaer.de/artikel/pharma-biotech/moderna-aktie-kennt-kein-halten-mehr-was-ist-mit-biontech-los-20409301.html
BioNTech: Triple buy recommendation - | is it starting now?: BioNTech receives positive analyst opinions after promising studies on Gotistobart and a combination ...
deraktionaer.de/artikel/pharma-biotech/biontech-dreifache-kaufempfehlung-gehts-jetzt-los-20408884.html
Paid articlePaywall BioNTech: mRNA Setback with Signal Effect - | Moderna's Fantasy Fizzles Out: Moderna Excites, BioNTech with Setback.
deraktionaer.de/artikel/pharma-biotech/biontech-mrna-rueckschlag-mit-signalwirkung-moderna-fantasie-verpufft-20407749.html
Barron's Aug 28
Paid articlePaywall BioNTech Stock Falls on Cancer Vaccine Setback: BioNTech says it is ending a Phase 2 trial for its investigational personalized mRNA cancer vaccine ...
barrons.com/articles/biontech-stock-cancer-vaccine-drug-trial-c0c772bc
Moderna kicks into high gear, BioNTech follows suit: Was this just the beginning?
deraktionaer.de/artikel/pharma-biotech/moderna-zuendet-den-turbo-biontech-zieht-nach-war-das-erst-der-auftakt-20407313.html
Paid articlePaywall Pharmaceuticals: Study success with cancer vaccine - | Moderna stock rises rapidly
handelsblatt.com/unternehmen/industrie/pharma-studienerfolg-bei-krebsimpfstoff-moderna-aktie-steigt-rasant/100248330.html
Barron's Aug 19
Paid articlePaywall BioNTech Stock Surges 20% on Moderna Cancer Vaccine Win. Why the Gains Could Fade.
barrons.com/articles/biontech-stock-moderna-cancer-vaccine-0925f6a6
Paid articlePaywall Moderna's share price soared: 177 percent increase - | Was this also the starting signal for BioNTech?
deraktionaer.de/artikel/deraktionaerplus/moderna-mit-kursfeuerwerk-177-prozent-plus-war-das-jetzt-auch-der-startschuss-fuer-biontech-20407124.html
Forecast lowered: Vaccine stockpiles full in Germany, BioNTech deep in the red: Weak demand for the Covid-19 vaccine has resulted in significant losses and a ...
manager-magazin.de/unternehmen/pharma/biontech-umsatzprognose-gesenkt-wegen-voller-impfstofflager-a-f3f45a40-8696-4407-8f52-03a4cf7a3981
Vaccine production: BioNTech closes plants - | and Berlin has a problem: The Mainz-based mRNA specialist BioNTech has decided to end vaccine production in ...
manager-magazin.de/unternehmen/biontech-schliessung-von-impfstoffanlagen-bringt-bundesregierung-in-bedraengnis-a-6b7d77e9-5b1b-4b1a-b2fa-0906b9384a50
BioNTech: Important data ahead: The oncology pipeline is being further advanced.
deraktionaer.de/artikel/pharma-biotech/biontech-wichtige-daten-voraus-20397791.html
BioNTech sues Moderna - | the details: BioNTech sues Moderna for patent infringement; shares of both companies remain stable.
deraktionaer.de/artikel/pharma-biotech/biontech-verklagt-moderna-die-details-20395822.html
Bayer sues COVID vaccine makers over mRNA technology: Bayer's Monsanto sued COVID-19 vaccine makers Pfizer , BioNTech and Moderna in Delaware federal court on ...
reuters.com/legal/litigation/bayer-sues-covid-vaccine-makers-over-mrna-technology-2026-01-06/
Patents: Corona vaccines - | Bayer sues BioNTech, Pfizer and Moderna: Bayer accuses several manufacturers of copying an old technology to produce mRNA vaccines ...
handelsblatt.com/unternehmen/industrie/patente-corona-impfstoffe-bayer-verklagt-biontech-pfizer-und-moderna/100189227.html
BioNTech stock: Hope is back: BioNTech acquires CureVac and strengthens market position; blockbuster potential for new cancer drug BNT327.
boerse-online.de/nachrichten/aktien/biontech-aktie-die-hoffnung-ist-zurueck-20392023.html
Share swap - | Biontech launches offer to Curevac shareholders: The deadline for the share swap is December 3rd. The former competitors plan to conduct joint ...
stuttgarter-nachrichten.de/inhalt.aktientausch-biontech-startet-angebot-an-curevac-aktionaere.9753c233-bf64-4877-8fed-36fe7b77f02d.html
European Patent Office declares Moderna mRNA patent invalid: The European Patent Office declared a contested mRNA patent owned by Moderna invalid ...
reuters.com/business/healthcare-pharmaceuticals/biontech-says-european-patent-office-has-declared-moderna-patent-invalid-2023-11-21/
Key FactsEuropean Patent Office invalidates Moderna patent in vaccine dispute
Nov 21, 2023 · Reading time: ~45 sec.
Summary created with AI assistance · Source: reuters.com
Summary created with AI assistance · Source: reuters.com
- The authority said its decision gave BioNTech and Pfizer a victory in the patent dispute between the vaccine makers.
- Moderna rejected the ruling and said it would file an appeal against the decision.
- Moderna shares were 2.3% lower in premarket trading on Wall Street after the announcement.
- Moderna sued BioNTech in Germany and other countries over allegedly copied mRNA technology it had patented long before 2019.
an important one, as we believe that this and others of Moderna's patents do not meet the requirements for grant and should never have been granted.— BioNTech, in a statement welcoming the EPO's decision
Next